Enter your email address in the box to the right of this page to receive email updates from the Life Sciences Hub when new content is published.
For those with an interest in life sciences, the rise to prominence of CRISPR, a transformational development in the field of molecular biology and genetics, has been impossible to ignore.
Welcome to our blog dedicated to Life Sciences. We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector. We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.
11 September 2019 - Posted by: Marc Döring
Late in 2018, medicinal cannabis was downgraded from Schedule 1 to Schedule 2 (medically allowed) in the Misuse of Drugs Regulations in the UK. The resulting flurry of activity in the mainstream news media about the use of cannabinoids and similar substances has been inescapable. Whilst there is arguably still a lot of hype around › Read More
03 September 2019 - Posted by: David Shen
On 26 August 2019, the China’s National People’s Congress passed the amended Drug Administration Law (the Amended DAL) which will take effect on 1 December. The new law brings in some changes while codifying many existing practices. We summarise in this article the key highlights, including intellectual property related rules, of the Amended DAL. 1. Redefine › Read More
28 August 2019 - Posted by: Eda Zhuleku
The new Law for More Safety in the Supply of Pharmaceuticals in Germany (Gesetz für mehr Sicherheit in der Arzneimittelversorgung- GSAV) which has been in force since 16 August amends the law regarding the prescription and sale of medical cannabis in Germany. Since 10 March 2017, it has been possible for medical cannabis to be prescribed › Read More
27 August 2019 - Posted by: Matthew Townsend
On 8 August 2019, the National Institute for Health and Care Excellence (NICE) published a draft guideline on prescribing cannabis-based medicinal products (the Draft Guideline) for consultation. The Draft Guideline, which, when finalised, will replace interim clinical guidance issued by specialist medical societies, makes recommendations regarding prescribing cannabis-based medicines for people with intractable nausea and › Read More
23 August 2019 - Posted by: Zuzana Hecko
On 21 August 2019 the Slovak government introduced a draft law which deletes CBD (cannabidiol) from the list of psychotropic substances and therefore makes CBD a non-regulated substance. CBD has been included on the list of psychotropic substances (category II) in Act No. 139/1998 (the Narcotics Act) since 2011. It was included on the list by › Read More